APA (7th ed.) Citation

Li, L. (2025). Disproportionate adverse event signals of selumetinib in neurofibromatosis type I: Insights from FAERS. Frontiers in pharmacology, 15, 1454418. https://doi.org/10.3389/fphar.2024.1454418

Chicago Style (17th ed.) Citation

Li, Lin. "Disproportionate Adverse Event Signals of Selumetinib in Neurofibromatosis Type I: Insights from FAERS." Frontiers in Pharmacology 15 (2025): 1454418. https://doi.org/10.3389/fphar.2024.1454418.

MLA (9th ed.) Citation

Li, Lin. "Disproportionate Adverse Event Signals of Selumetinib in Neurofibromatosis Type I: Insights from FAERS." Frontiers in Pharmacology, vol. 15, 2025, p. 1454418, https://doi.org/10.3389/fphar.2024.1454418.